Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2346-2352

  Bian, S X ^a,b   Kuban, D A ^a   Levy, L B ^a   Oh, J ^a   Castle, K O ^a   Pugh, T J ^a   Choi, S ^a   Mcguire, S E ^a   Nguyen, Q N ^a   Frank, S J ^a   Nguyen, P L ^c   Lee, A K ^a   Hoffman, K E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen deprivation therapy; Comorbidity; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FAILURE FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; SHORT COURSE THERAPY; SURVIVAL TIME; TREATMENT DURATION;

EID: 84865561659     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds001     Document Type: Article

References (23)

1. Kuban DA, Levy LB, Cheung MR et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011; 79: 1310-1317.
2. Pollack A, Zagars GK, Antolak JA et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002; 54: 677-685.
3. Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-1996.
4. Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-1239.
5. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118.
6. Denham JW, Steigler A, Lamb DS et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850.
7. Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459.
8. D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827.
9. Lau WK, Blute ML, Bostwick DG et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001; 166: 1692-1697.
10. Piccirillo JF, Tierney RM, Costas I et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447.
11. StataCorp. Stata Statistical Software: Release 11 College Station, TX: StataCorp LP 2009.
12. SAS Institute Inc. SAS/STAT® 9.2 User's Guide Cary, NC: SAS Institute Inc. 2008.
13. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing 2010. ISBN 3-900051-07-0, http://www.R-project.org/.
14. Atkinson TM, Atkinson B. R part by Brian Ripley. (2010). rpart: Recursive Partitioning. R package version 3.1-48. http://CRAN.R-project.org/package=rpart. (26 August 2011, date last accessed).
15. Valicenti RK, Bae K, Michalski J et al. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys 2011; 79: 1323-1329.
16. Zelefsky MJ, Yamada Y, Fuks Z et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71: 1028-1033.
17. Stark JR, Perner S, Stampfer MJ et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?. J Clin Oncol 2009; 27: 3459-3464.
18. Kestin LL, Goldstein NS, Vicini FA et al. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 2002; 168: 1994-1999.
19. Liauw SL, Fricano J, Correa D et al. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer 2009; 115: 1784-1790.
20. Qian Y, Feng FY, Halverson S et al. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81(3): e135-e142.
21. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61: 32-38.
22. Nguyen PL, Chen MH, Beard CJ et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010; 77: 1046-1052.
23. D'Amico AV, Chen MH, Renshaw AA et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-295.